Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030
Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) of both younger and elderly population and was defined as EBV-positive monoclonal extensive B-cell proliferative disease. The survival of patients with EBV-positive DLBCL is significantly worse than that of patients with EBV-negative DLBCL. Cells with latent EBV infection express EBER protein and may express other proteins such as EBNA and LMP proteins. EBV also induces the NFκB pathway, which may be required for the survival of the cells in DLBCL. The immunohistochemical profile is generally positive for B-cell markers CD20, CD19, CD79a, and PAX-5. CD10 and BCL6 are usually negative, while MUM1 is commonly positive. Cases with immunoblastic or plasmablastic features may lack CD20 expression. In situ hybridization for EBER is positive and is considered the most crucial test in diagnosis, with the highest diagnostic sensitivity. EBV+ DLBCL has a poor response to treatment, so rapid detection is necessary.
The
prevalence of EBV positive DLBCL was 14.0% and 10.4% for EBER cut-off of 20%
and 50%, respectively.
The EBV
positive DLBCL of the elderly accounts for 8.7%–11.4% of all DLBCL in Asian
countries, less than 5% in western nations. Since the introduction of
rituximab, R-CHOP has become the standard treatment for CD20 positive DLBCL.
The competitive
landscape of Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma includes
country-specific approved and pipeline therapies. Any asset/product-specific
designation or review and Accelerated Approval are tracked and supplemented
with analyst commentary.
KOLs insights of Epstein
Barr Virus-Positive Diffuse Large B-cell Lymphoma across 8 MM market from the center
of Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Epstein
Barr Virus-Positive Diffuse Large B-cell Lymphoma Market Forecast:
Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data
Inputs with sourcing, Market Event, and Product Event, Country specific
Forecast Model, Market uptake and patient share uptake, Attribute Analysis,
Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
S. No Asset Company Stage
1 nanatinostat and valganciclovir (Nana-val) Viracta Therapeutics Phase 2
Comments
Post a Comment